semaglutide sglt2 inhibitor The Future of Type 2 Diabetes Management: Semaglutide, Inhibitors, and Canagliflozin Combining GLP-1 Receptor Agonists and

during or within 14 days following administration of monoamine oxidase inhibitors

Module VIManagement and reporting of adverse reactions to medicinal products (Rev 1) (EMA/873138/2011 Rev 1)

Despite the current dominance of injectables, patient preference for simpler oral formulations is growing, especially as a result of continuous international product launches

Administered as a once-weekly subcutaneous injection, it works by mimicking the action of the naturally occurring hormone GLP-1, which stimulates insulin secretion in response to elevated blood glucose levels, suppresses glucagon release, and slows gastric emptying